- Home
- NET vs EW Comparison
NET vs EW Comparison
Compare NET & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NET | EW |
|---|---|---|
| Founded | 2009 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.5B | 49.5B |
| IPO Year | 2019 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NET | EW |
|---|---|---|
| Price | $172.11 | $78.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 21 |
| Target Price | ★ $229.38 | $96.79 |
| AVG Volume (30 Days) | ★ 5.0M | 3.9M |
| Earning Date | 02-10-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.33 |
| Revenue | $2,013,376,000.00 | ★ $5,883,800,000.00 |
| Revenue This Year | $29.73 | $14.29 |
| Revenue Next Year | $27.56 | $9.73 |
| P/E Ratio | ★ N/A | $33.52 |
| Revenue Growth | ★ 28.07 | 10.60 |
| 52 Week Low | $89.42 | $65.94 |
| 52 Week High | $260.00 | $87.89 |
Technical Indicators
Market Signals| Indicator | NET | EW |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 31.27 |
| Support Level | $162.01 | $77.46 |
| Resistance Level | $185.22 | $83.77 |
| Average True Range (ATR) | 10.68 | 1.82 |
| MACD | -1.49 | -0.56 |
| Stochastic Oscillator | 5.32 | 8.82 |
Price Performance
Historical ComparisonAbout NET Cloudflare Inc.
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy and execute code without maintaining servers.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.